98%
921
2 minutes
20
Glycyrrhizin-enriched extracts from licorice root are associated with numerous health benefits and are widely used in phytotherapy. There is evidence that ingesting glycyrrhizin beyond threshold concentrations can impact the metabolism of cortisol, inhibiting its conversion to an inactive form, cortisone, via 11-hydroxysteroid dehydrogenase. A consequence can be a form of hypermineralocorticoidism, with elevated potassium excretion and associated hypertension, as demonstrated in rats and humans. Here, 3 orally dosed concentrations of glycyrrhizin (0.2, 0.4 and 0.6 mg/kg bodyweight/day) were assessed over 28 days in dogs. As the current guidelines reflect a lack of reliable data in this species, our aim was to provide relevant information for doses above the current guidelines. The specific purpose of this study was to demonstrate that an intake of licorice with a known therapeutic benefit to dogs does not cause hypermineralocorticoidism in this species. No changes in blood pressure, nor electrolyte excretion were observed in the dogs given these three glycyrrhizin concentrations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jpn.14030 | DOI Listing |
Emerg Med Australas
October 2025
Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.
View Article and Find Full Text PDFCirc Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
High Alt Med Biol
September 2025
International Commission for Mountain Emergency Medicine (ICAR MEDCOM), Zurich, Switzerland.
McLaughlin, Kyle, Charley Shimanski, Ken Zafren, Ian Jackson, Gerold Biner, Maurizio Folini, Andreas Hermansky, Eric Ridington, Peter Hicks, Giacomo Strapazzon, Marika Falla, Alastair Hopper, Dave Weber, Ryan Jackson, and Hermann Brugger. Helicopter rescue at very high altitude: Recommendations of the International Commission for Mountain Emergency Medicine (ICAR MedCom) 2025. 00:00-00, 2025.
View Article and Find Full Text PDFExpert Rev Respir Med
September 2025
Department of General Thoracic Surgery, Social Welfare Organization Saiseikai Imperial Gift Foundation, Chibaken Saiseikai Narashino Hospital, Chiba, Japan.
Introduction: PubMed was used for a literature search (1990-2025) on the minimally invasive surgical approaches for pneumothorax, which have evolved markedly, with video-assisted thoracic surgery (VATS) emerging as a preferred procedure. Systematic reviews of randomized control trials indicate that VATS is less invasive than traditional thoracotomy. Furthermore, uniportal VATS provides less postoperative pain and better cosmetic outcomes than thoracotomy.
View Article and Find Full Text PDFBMC Health Serv Res
September 2025
Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Seebad 82/83, Rüdersdorf, 15562, Germany.
Background: Hypertension remains a critical public health issue in Germany, affecting millions of individuals. Mobile health applications (mHealth apps) offer promising solutions for improving patient outcomes and adherence in hypertension management. Despite their advantages in healthcare, the adoption of mHealth apps by general practitioners (GPs) in Germany remains limited to date.
View Article and Find Full Text PDF